Corbus Pharmaceuticals ($CRBP) reported that the FDA has rejected its request for Breakthrough Therapy status for anabasum (Resunab) for systemic sclerosis. The drug candidate already has Orphan Drug status for Fast Track review for the indication. The company expects to carry out a Phase III study in the fourth quarter.
Pulmatrix ($PULM) has been granted the U.S. Patent #9,642,798 by the USPTO. The patent covers the company’s lead candidate PUR0200 for the potential treatment of chronic obstructive pulmonary disease (COPD), the sixth U.S. patent protecting the product. In clinical studies, PUR0200 has been up to five times more efficient in delivering the drug to the lungs than currently marketed offerings.